{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:39:25Z","timestamp":1793165965624,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["109-2314-B-002-036-MY3"],"award-info":[{"award-number":["109-2314-B-002-036-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["111-2314-B-002-063"],"award-info":[{"award-number":["111-2314-B-002-063"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dental Sciences"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jds.2025.02.002","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T12:33:08Z","timestamp":1739277188000},"page":"729-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy"],"prefix":"10.1016","volume":"20","author":[{"given":"Ling-Ying","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ming","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-8852","authenticated-orcid":false,"given":"Sang-Heng","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Hong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jung","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yih","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-0840","authenticated-orcid":false,"given":"Jang-Jaer","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jds.2025.02.002_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","article-title":"The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.jds.2025.02.002_bib2","first-page":"283","article-title":"Bone mineral density in adults in taiwan: results of the nutrition and health survey in Taiwan 2005-2008 (NAHSIT 2005-2008)","volume":"20","author":"Lin","year":"2011","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.jds.2025.02.002_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bj.2018.08.001","article-title":"Secular trends in incidence of osteoporosis in Taiwan: a nationwide population-based study","volume":"41","author":"Chen","year":"2018","journal-title":"Biomed J"},{"key":"10.1016\/j.jds.2025.02.002_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"S\u00f6zen","year":"2017","journal-title":"Eur J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.jds.2025.02.002_bib5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jfma.2023.01.007","article-title":"Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update","volume":"122","author":"Tai","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jds.2025.02.002_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2474-12-105","article-title":"Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study","volume":"12","author":"Panula","year":"2011","journal-title":"BMC Muscoskelet Disord"},{"key":"10.1016\/j.jds.2025.02.002_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","article-title":"Osteoanabolic agents for osteoporosis","volume":"2","author":"Haas","year":"2018","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jds.2025.02.002_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2174\/0929867327666200330142432","article-title":"Osteoporosis: mechanism, molecular target and current status on drug development","volume":"28","author":"Li","year":"2021","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jds.2025.02.002_bib9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib10","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib12","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","article-title":"What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review","volume":"45","author":"Aljohani","year":"2017","journal-title":"J Cranio-Maxillo-Fac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.oooo.2018.08.015","article-title":"Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study","volume":"126","author":"Hallmer","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jds.2025.02.002_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196419","article-title":"The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects","volume":"13","author":"Chiu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jds.2025.02.002_bib16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","article-title":"Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies","volume":"112","author":"Fehm","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jds.2025.02.002_bib17","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jds.2025.02.002_bib18","first-page":"38","article-title":"Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update","volume":"36","author":"Utreja","year":"2013","journal-title":"Odonto-Stomatol Trop"},{"key":"10.1016\/j.jds.2025.02.002_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jds.2025.02.002_bib20","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jds.2025.02.002_bib21","first-page":"769","article-title":"Risk of developing BRONJ among patients exposed to intravenous bisphosphonates following tooth extraction","volume":"45","author":"Sanchis","year":"2014","journal-title":"Quintessence Int"},{"key":"10.1016\/j.jds.2025.02.002_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1563\/aaid-joi-16-00057","article-title":"Medication-related osteonecrosis of the jaw and dental implants failures: a systematic review","volume":"43","author":"Guazzo","year":"2017","journal-title":"J Oral Implantol"},{"key":"10.1016\/j.jds.2025.02.002_bib23","first-page":"e195","article-title":"Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: systematic review","volume":"24","author":"Granate-Marques","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.jds.2025.02.002_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1563\/aaid-joi-D-19-00088","article-title":"Success rate and safety of dental implantology in patients treated with antiresorptive medication: a systematic review","volume":"47","author":"Papadakis","year":"2021","journal-title":"J Oral Implantol"},{"key":"10.1016\/j.jds.2025.02.002_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/SCS.0000000000002564","article-title":"Medication-related osteonecrosis of the jaw around dental implants: implant surgery-triggered or implant presence-triggered osteonecrosis?","volume":"27","author":"Giovannacci","year":"2016","journal-title":"J Craniofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib26","doi-asserted-by":"crossref","first-page":"1937.e1","DOI":"10.1016\/j.joms.2014.04.037","article-title":"Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws","volume":"72","author":"Holzinger","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.jds.2025.02.002_bib28","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: a systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis"},{"key":"10.1016\/j.jds.2025.02.002_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jds.2025.02.002_bib31","first-page":"63","article-title":"The prevention of medication-related osteonecrosis of the jaw","volume":"114","author":"Poxleitner","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.jds.2025.02.002_bib32","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40902-021-00310-w","article-title":"Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment","volume":"43","author":"Lee","year":"2021","journal-title":"Maxillofac Plast Reconstr Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jds.2025.02.002_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jds.2025.02.002_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jds.2025.02.002_bib36","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jds.2025.02.002_bib37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jds.2025.02.002_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jds.2025.02.002_bib39","first-page":"7","article-title":"Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis","volume":"7","author":"Inderjeeth","year":"2015","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.jds.2025.02.002_bib40","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6910312","article-title":"RANKL\/RANK\/OPG Pathway: a mechanism involved in exercise-induced bone remodeling","volume":"2020","author":"Tobeiha","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jds.2025.02.002_bib42","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jds.2025.02.002_bib43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jbmr.3019","article-title":"Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study","volume":"32","author":"Choi","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jds.2025.02.002_bib44","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3390\/jcm13072040","article-title":"Comparison of the efficacy of zoledronate and denosumab in patients with acute osteoporotic vertebral compression fractures: a randomized controlled trial","volume":"13","author":"Son","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jds.2025.02.002_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","article-title":"Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours","volume":"51","author":"Gibiansky","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jds.2025.02.002_bib46","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jds.2025.02.002_bib47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.jds.2025.02.002_bib48","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1017391","article-title":"Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database","volume":"13","author":"Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jds.2025.02.002_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.11005\/jbm.2021.28.4.279","article-title":"Medication related osteonecrosis of the jaw: 2021 position statement of the Korean society for bone and mineral Research and the Korean association of oral and maxillofacial Surgeons","volume":"28","author":"Kim","year":"2021","journal-title":"J Bone Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib51","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00198-023-06818-3","article-title":"Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan","volume":"34","author":"Liu","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jds.2025.02.002_bib52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib53","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jds.2025.02.002_bib54","article-title":"Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: a prospective cohort study","volume":"14","author":"Tsuchiya","year":"2021","journal-title":"BoneKEy Rep"},{"key":"10.1016\/j.jds.2025.02.002_bib55","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.jds.2025.02.002_bib56","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jds.2025.02.002_bib57","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jds.2025.02.002_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.jds.2025.02.002_bib59","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","article-title":"Inhibition of oral mucosal cell wound healing by bisphosphonates","volume":"66","author":"Landesberg","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib60","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1078-0432.CCR-10-1614","article-title":"Effect of zoledronate on oral wound healing in rats","volume":"17","author":"Yamashita","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jds.2025.02.002_bib61","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00774-009-0128-9","article-title":"Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice","volume":"28","author":"Kobayashi","year":"2010","journal-title":"J Bone Miner Metabol"},{"key":"10.1016\/j.jds.2025.02.002_bib62","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jds.2025.02.002_bib63","article-title":"Risk factors influencing medication-related osteonecrosis of the jaws (MRONJ) following dental extraction among osteoporotic patients in Taiwan","author":"Wei","year":"2024","journal-title":"Head Neck"},{"key":"10.1016\/j.jds.2025.02.002_bib64","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jds.2025.02.002_bib65","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.tripleo.2008.03.005","article-title":"Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications","volume":"106","author":"Migliorati","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jds.2025.02.002_bib66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/039463201202500138","article-title":"Possible role of oral ibandronate administration in Osteonecrosis of the Jaw: a case report","volume":"25","author":"Notarnicola","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jds.2025.02.002_bib67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4103\/2230-8210.95711","article-title":"Osteonecrosis of jaw associated with bisphosphonate use","volume":"16","author":"Rastogi","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib68","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib69","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jds.2025.02.002_bib70","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","article-title":"Drug therapy for osteoporosis in older adults","volume":"399","author":"Reid","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jds.2025.02.002_bib71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1634\/theoncologist.5-5-388","article-title":"Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects","volume":"5","author":"Muchmore","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.jds.2025.02.002_bib72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00003495-200060020-00013","article-title":"Raloxifene: a review of its use in postmenopausal osteoporosis","volume":"60","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jds.2025.02.002_bib73","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jds.2025.02.002_bib74","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S8756-3282(01)00685-8","article-title":"The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in\u00a0vitro","volume":"30","author":"Taranta","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.jds.2025.02.002_bib75","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1097\/SCS.0000000000004278","article-title":"Mandibular osteonecrosis associated with raloxifene","volume":"29","author":"Pontes","year":"2018","journal-title":"J Craniofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib76","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2013-4119","article-title":"The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib77","first-page":"499","article-title":"Teriparatide in the management of osteoporosis","volume":"2","author":"Bodenner","year":"2007","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jds.2025.02.002_bib78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/0022034511407920","article-title":"Short-term teriparatide delivery and osseointegration: a clinical feasibility study","volume":"90","author":"Kuchler","year":"2011","journal-title":"J Dent Res"},{"key":"10.1016\/j.jds.2025.02.002_bib79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.archoralbio.2019.04.007","article-title":"Teriparatide improves alveolar bone modelling after tooth extraction in orchiectomized rats","volume":"102","author":"de Oliveira Puttini","year":"2019","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.jds.2025.02.002_bib80","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jds.2025.02.002_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jds.2025.02.002_bib82","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.2147\/DDDT.S127568","article-title":"Profile of romosozumab and its potential in the management of osteoporosis","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jds.2025.02.002_bib83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.coph.2018.04.011","article-title":"Targeting WNT signaling in the treatment of osteoporosis","volume":"40","author":"Baron","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jds.2025.02.002_bib84","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1210\/jc.2019-00924","article-title":"Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jds.2025.02.002_bib85","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jds.2025.02.002_bib86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jds.2025.02.002_bib87","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","volume":"73","author":"Loyson","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.jds.2025.02.002_bib88","article-title":"Interventions for replacing missing teeth: different times for loading dental implants","volume":"2013","author":"Esposito","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jds.2025.02.002_bib89","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-051X.2008.01246.x","article-title":"Modeling and remodeling of human extraction sockets","volume":"35","author":"Trombelli","year":"2008","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.jds.2025.02.002_bib90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5125\/jkaoms.2023.49.2.75","article-title":"Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis","volume":"49","author":"Mustakim","year":"2023","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"10.1016\/j.jds.2025.02.002_bib91","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/j.oooo.2011.11.037","article-title":"Atraumatic vertical tooth extraction: a proof of principle clinical study of a novel system","volume":"116","author":"Muska","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jds.2025.02.002_bib92","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00784-016-1762-y","article-title":"Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab","volume":"21","author":"Matsumoto","year":"2017","journal-title":"Clin Oral Invest"},{"key":"10.1016\/j.jds.2025.02.002_bib93","first-page":"197","article-title":"Occlusal pressure pattern analysis of complete dentures for evaluation of occlusal adjustment","volume":"51","author":"Okuma","year":"2004","journal-title":"J Med Dent Sci"},{"key":"10.1016\/j.jds.2025.02.002_bib94","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1034\/j.1601-0825.2002.01789.x","article-title":"Oral mucosal conditions in elderly dental patients","volume":"8","author":"Jainkittivong","year":"2002","journal-title":"Oral Dis"},{"key":"10.1016\/j.jds.2025.02.002_bib95","first-page":"62","article-title":"Buccal exostosis: a rare entity","volume":"7","author":"Medsinge","year":"2015","journal-title":"J Int Oral Health"},{"key":"10.1016\/j.jds.2025.02.002_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.oooo.2019.07.046","article-title":"Mandibular and palatal tori exposed by trauma are risk factors for medication-related osteonecrosis of the jaws: a report from the Copenhagen ONJ cohort","volume":"129","author":"Schi\u00f8dt","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jds.2025.02.002_bib97","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00774-020-01195-x","article-title":"Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer","volume":"39","author":"Ueda","year":"2021","journal-title":"J Bone Miner Metabol"},{"key":"10.1016\/j.jds.2025.02.002_bib98","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1111\/odi.14887","article-title":"Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Bedogni","year":"2024","journal-title":"Oral Dis"},{"key":"10.1016\/j.jds.2025.02.002_bib99","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.joen.2020.04.010","article-title":"Pulpal disease arising from medication-related osteonecrosis of the jaw: a case report","volume":"46","author":"Kiho","year":"2020","journal-title":"J Endod"},{"key":"10.1016\/j.jds.2025.02.002_bib100","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3190301","article-title":"Radiographic findings in patients with medication-related osteonecrosis of the jaw","volume":"2017","author":"Cardoso","year":"2017","journal-title":"Int J Dent"},{"key":"10.1016\/j.jds.2025.02.002_bib101","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5624\/isd.2020.50.4.273","article-title":"Several issues regarding the diagnostic imaging of medication-related osteonecrosis of the jaw","volume":"50","author":"Kim","year":"2020","journal-title":"Imaging Sci Dent"}],"container-title":["Journal of Dental Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1991790225000340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1991790225000340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:24:05Z","timestamp":1743128645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1991790225000340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1991790225000340"],"URL":"https:\/\/doi.org\/10.1016\/j.jds.2025.02.002","relation":{},"ISSN":["1991-7902"],"issn-type":[{"value":"1991-7902","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Dental Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jds.2025.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}